Enhanced suicide gene effect by adenoviral transduction of aVP22-cytosine deaminase (CD) fusion gene

Gene Therapy

Volumn 8, Issue 21, 2001, Pages 1654-1664

  Wybranietz, W A ^a   Gross C D ^a   Phelan, A ^b   O'Hare, P ^b   Spiegel, M ^a   Graepler, F ^a   Bitzer, M ^a   Stahler P ^a   Gregor, M ^a   Lauer, U M ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b MARIE CURIE RESEARCH INSTITUTE   (United Kingdom)

Author keywords

E. coli CD; HSV 1; Intracellular trafficking; Protein delivery; Suicide gene; VP22

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; POLYPEPTIDE; VIRUS FUSION PROTEIN; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL NUCLEUS; CELL TRANSPORT; CONTROLLED STUDY; CYTOTOXICITY; ESCHERICHIA COLI; FUSION GENE; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; SOLID TUMOR; STAINING; SUICIDE GENE;

ADENOVIRIDAE; ANIMALS; COS CELLS; CYTOSINE DEAMINASE; ESCHERICHIA COLI PROTEINS; FEMALE; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NUCLEOSIDE DEAMINASES; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC; UTERINE CERVICAL NEOPLASMS; VIRAL STRUCTURAL PROTEINS;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; ESCHERICHIA COLI; HUMAN HERPESVIRUS 1;

EID: 0035177693     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301564     Document Type: Article

References (55)

1. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir
2. A phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma
3. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
4. A first step in the development of gene therapy for colorectal carcinoma: Cloning, sequencing, and expression of Escherichia coli cytosine deaminase
5. Characterization of the Escherichia coli codBA operon encoding cytosine permease and cytosine deaminase
6. Regional 'pro-drug' gene therapy: Intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic carcinoma
7. Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine
8. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene
9. Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver
10. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory
11. Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy
12. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild-type tumor
13. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase
14. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo
15. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine
16. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine
17. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase
18. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma
19. Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line
20. Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice
21. Curative potential of herpes simplex virus thymidine kinase gene transfer in rats with 9L gliosarcoma
22. Gene therapy on trial
23. Intercellular trafficking and protein delivery by a herpesvirus structural protein
24. Herpes simplex virus type 1 tegument protein VP22 induces the stabilization and hyperacetylation of microtubules
25. Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines
26. Intercellular delivery of functional p53 by the herpesvirus protein VP22
27. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22
28. New colorimetric cytotoxicity assay for anticancer-drug screening
29. Growth characteristics and imaging properties of the Morris hepatoma 3924A in ACI rats: A suitable model for transarterial chemoembolization
30. Intercellular spread of GFP-VP22
31. Evaluation of VP22 spread in tissue culture
32. Direct protein transfer to terminally differentiated muscle
33. Understanding, improving and using green fluorescent proteins
34. Comparison of sulforhodamine B, tetrazolium and clonogenic assays for in vitro radiosensitivity testing in human ovarian cell lines
35. A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines
36. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity
37. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines
38. Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: Possible factor in 5-fluorocytosine clinical toxicity
39. Modified VP22 localizes to the cell nucleus during synchronized herpes simplex virus type 1 infection
40. Distinctions between bovine herpesvirus 1 and herpes simplex virus type 1 VP22 tegument protein subcellular associations
41. Intercellular trafficking of VP22-GFP fusion proteins
42. Cytoplasm-to-nucleus translocation of a herpesvirus tegument protein during cell division
43. Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine
44. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase
45. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene
46. Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma
47. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization
48. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli
49. The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2
50. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity
51. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system
52. Distinct combination of purification methods dramatically improves cohesive-end subcloning of PCR products
53. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system
54. Methods for construction of adenovirus vectors
55. Detection of wild-type contamination in a recombinant adenoviral preparation by PCR